View Financial HealthThis company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsGenocea Biosciences 配当と自社株買い配当金 基準チェック /06Genocea Biosciences配当金を支払った記録がありません。主要情報n/a配当利回り-134,246.3%バイバック利回り総株主利回り-134,246.3%将来の配当利回りn/a配当成長n/a次回配当支払日n/a配当落ち日n/a一株当たり配当金n/a配当性向n/a最近の配当と自社株買いの更新更新なしすべての更新を表示Recent updatesPrice Target Changed • Apr 27Price target decreased to US$5.74Down from US$6.74, the current price target is an average from 5 analysts. New target price is 1,300% above last closing price of US$0.41. Stock is down 84% over the past year. The company is forecast to post a net loss per share of US$0.78 next year compared to a net loss per share of US$0.48 last year.Price Target Changed • Apr 11Price target decreased to US$5.74Down from US$6.70, the current price target is an average from 5 analysts. New target price is 857% above last closing price of US$0.60. Stock is down 77% over the past year. The company is forecast to post a net loss per share of US$0.75 next year compared to a net loss per share of US$0.48 last year.Reported Earnings • Mar 13Full year 2021 earnings: EPS misses analyst expectationsFull year 2021 results: US$0.48 loss per share (up from US$0.98 loss in FY 2020). Net loss: US$33.2m (loss narrowed 24% from FY 2020). Products in clinical trials Phase I: 2 Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 77%. Over the next year, revenue is expected to shrink by 100% compared to a 60% growth forecast for the pharmaceuticals industry in the US. Over the last 3 years on average, earnings per share has increased by 54% per year but the company’s share price has fallen by 42% per year, which means it is significantly lagging earnings.Price Target Changed • Mar 11Price target increased to US$7.67Up from US$6.68, the current price target is an average from 3 analysts. New target price is 555% above last closing price of US$1.17. Stock is down 60% over the past year. The company is forecast to post a net loss per share of US$0.46 next year compared to a net loss per share of US$0.98 last year.Board Change • Dec 06Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 7 experienced directors. 3 highly experienced directors. Independent Director Jennifer Herron was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Reported Earnings • Oct 30Third quarter 2021 earnings released: US$0.052 loss per share (vs US$0.082 loss in 3Q 2020)Third quarter 2021 results: Net loss: US$3.62m (loss narrowed 21% from 3Q 2020). Over the last 3 years on average, earnings per share has increased by 60% per year but the company’s share price has fallen by 28% per year, which means it is significantly lagging earnings.分析記事 • Jun 17Here's Why Shareholders May Want To Be Cautious With Increasing Genocea Biosciences, Inc.'s (NASDAQ:GNCA) CEO Pay PacketThe underwhelming share price performance of Genocea Biosciences, Inc. ( NASDAQ:GNCA ) in the past three years would...Executive Departure • Apr 16Independent Director has left the companyOn the 12th of April, Ronald H. Cooper's tenure as Independent Director ended after 4.8 years in the role. We don't have any record of a personal shareholding under Ronald H.'s name. A total of 2 executives have left over the last 12 months.Recent Insider Transactions Derivative • Feb 21President exercised options to buy US$132k worth of stock.On the 17th of February, William Clark exercised options to buy 36k shares at a strike price of around US$2.24, costing a total of US$82k. This transaction amounted to 165% of their direct individual holding at the time of the trade. Since March 2020, William's direct individual holding has increased from 17.42k shares to 19.75k. Company insiders have collectively bought US$92k more than they sold, via options and on-market transactions, in the last 12 months.分析記事 • Feb 18What Type Of Returns Would Genocea Biosciences'(NASDAQ:GNCA) Shareholders Have Earned If They Purchased Their SharesFive Years Ago?Genocea Biosciences, Inc. ( NASDAQ:GNCA ) shareholders will doubtless be very grateful to see the share price up 77% in...Analyst Estimate Surprise Post Earnings • Feb 12Earnings beat expectations, revenue disappointsRevenue missed analyst estimates by 2.9%. Earnings per share (EPS) exceeded analyst estimates by 2.9%. Over the next year, revenue is expected to shrink by 67% compared to a 819% growth forecast for the Biotechs industry in the US.Is New 90 Day High Low • Feb 04New 90-day high: US$3.30The company is up 37% from its price of US$2.41 on 05 November 2020. The American market is up 16% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 24% over the same period.分析記事 • Jan 14How Much Of Genocea Biosciences, Inc. (NASDAQ:GNCA) Do Institutions Own?Every investor in Genocea Biosciences, Inc. ( NASDAQ:GNCA ) should be aware of the most powerful shareholder groups...Is New 90 Day High Low • Dec 24New 90-day high: US$2.67The company is up 26% from its price of US$2.12 on 24 September 2020. The American market is up 18% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 23% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.Is New 90 Day High Low • Oct 31New 90-day low: US$2.08The company is down 27% from its price of US$2.85 on 31 July 2020. The American market is up 3.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 2.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is US$11.76 per share.Analyst Estimate Surprise Post Earnings • Oct 31Third-quarter earnings released: Earnings beat expectationsEarnings per share (EPS) surpassed analyst estimates by 69% at -US$0.08. Revenue is expected to shrink by 76% over the next year, compared to a 293% growth forecast for the Biotechs industry in the US.Major Estimate Revision • Oct 30Analysts increase EPS estimates to -US$1.07The 2020 consensus revenue estimate increased from US$922.4k to US$937.3k. Analysts raised their EPS forecasts from -US$1.21 to -US$1.07 in 2020. The Biotechs industry in the US is expected to see an average net income growth of 6.3% next year. The consensus price target of US$9.40 was unchanged from the last update. Share price is down by 8.6% to US$2.12 over the past week.Major Estimate Revision • Sep 18Analysts update estimatesThe 2020 consensus revenue estimate increased from US$722.4k to US$922.4k. Earning per share (EPS) estimate remained mostly unchanged at -US$1.21. The Biotechs industry in the US is expected to see a 17% decline in net income next year. The consensus price target of US$9.40 was unchanged from the last update. Share price is up 17% to US$2.54 over the past week.決済の安定と成長配当データの取得安定した配当: GNCA.Qの 1 株当たり配当が過去に安定していたかどうかを判断するにはデータが不十分です。増加する配当: GNCA.Qの配当金が増加しているかどうかを判断するにはデータが不十分です。配当利回り対市場Genocea Biosciences 配当利回り対市場GNCA.Q 配当利回りは市場と比べてどうか？セグメント配当利回り会社 (GNCA.Q)n/a市場下位25% (US)1.4%市場トップ25% (US)4.2%業界平均 (Biotechs)2.4%アナリスト予想 (GNCA.Q) (最長3年)n/a注目すべき配当: GNCA.Qは最近配当金を報告していないため、配当金支払者の下位 25% に対して同社の配当利回りを評価することはできません。高配当: GNCA.Qは最近配当金を報告していないため、配当金支払者の上位 25% に対して同社の配当利回りを評価することはできません。株主への利益配当収益カバレッジ: GNCA.Qの 配当性向 を計算して配当金の支払いが利益で賄われているかどうかを判断するにはデータが不十分です。株主配当金キャッシュフローカバレッジ: GNCA.Qが配当金を報告していないため、配当金の持続可能性を計算できません。高配当企業の発掘7D1Y7D1Y7D1YUS 市場の強力な配当支払い企業。View Management企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2023/05/23 18:42終値2023/05/23 00:00収益2022/03/31年間収益2021/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Genocea Biosciences, Inc. これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。9 アナリスト機関Michael UlzBairdMara GoldsteinCantor Fitzgerald & Co.Joseph PantginisH.C. Wainwright & Co.6 その他のアナリストを表示
Price Target Changed • Apr 27Price target decreased to US$5.74Down from US$6.74, the current price target is an average from 5 analysts. New target price is 1,300% above last closing price of US$0.41. Stock is down 84% over the past year. The company is forecast to post a net loss per share of US$0.78 next year compared to a net loss per share of US$0.48 last year.
Price Target Changed • Apr 11Price target decreased to US$5.74Down from US$6.70, the current price target is an average from 5 analysts. New target price is 857% above last closing price of US$0.60. Stock is down 77% over the past year. The company is forecast to post a net loss per share of US$0.75 next year compared to a net loss per share of US$0.48 last year.
Reported Earnings • Mar 13Full year 2021 earnings: EPS misses analyst expectationsFull year 2021 results: US$0.48 loss per share (up from US$0.98 loss in FY 2020). Net loss: US$33.2m (loss narrowed 24% from FY 2020). Products in clinical trials Phase I: 2 Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 77%. Over the next year, revenue is expected to shrink by 100% compared to a 60% growth forecast for the pharmaceuticals industry in the US. Over the last 3 years on average, earnings per share has increased by 54% per year but the company’s share price has fallen by 42% per year, which means it is significantly lagging earnings.
Price Target Changed • Mar 11Price target increased to US$7.67Up from US$6.68, the current price target is an average from 3 analysts. New target price is 555% above last closing price of US$1.17. Stock is down 60% over the past year. The company is forecast to post a net loss per share of US$0.46 next year compared to a net loss per share of US$0.98 last year.
Board Change • Dec 06Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 7 experienced directors. 3 highly experienced directors. Independent Director Jennifer Herron was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Reported Earnings • Oct 30Third quarter 2021 earnings released: US$0.052 loss per share (vs US$0.082 loss in 3Q 2020)Third quarter 2021 results: Net loss: US$3.62m (loss narrowed 21% from 3Q 2020). Over the last 3 years on average, earnings per share has increased by 60% per year but the company’s share price has fallen by 28% per year, which means it is significantly lagging earnings.
分析記事 • Jun 17Here's Why Shareholders May Want To Be Cautious With Increasing Genocea Biosciences, Inc.'s (NASDAQ:GNCA) CEO Pay PacketThe underwhelming share price performance of Genocea Biosciences, Inc. ( NASDAQ:GNCA ) in the past three years would...
Executive Departure • Apr 16Independent Director has left the companyOn the 12th of April, Ronald H. Cooper's tenure as Independent Director ended after 4.8 years in the role. We don't have any record of a personal shareholding under Ronald H.'s name. A total of 2 executives have left over the last 12 months.
Recent Insider Transactions Derivative • Feb 21President exercised options to buy US$132k worth of stock.On the 17th of February, William Clark exercised options to buy 36k shares at a strike price of around US$2.24, costing a total of US$82k. This transaction amounted to 165% of their direct individual holding at the time of the trade. Since March 2020, William's direct individual holding has increased from 17.42k shares to 19.75k. Company insiders have collectively bought US$92k more than they sold, via options and on-market transactions, in the last 12 months.
分析記事 • Feb 18What Type Of Returns Would Genocea Biosciences'(NASDAQ:GNCA) Shareholders Have Earned If They Purchased Their SharesFive Years Ago?Genocea Biosciences, Inc. ( NASDAQ:GNCA ) shareholders will doubtless be very grateful to see the share price up 77% in...
Analyst Estimate Surprise Post Earnings • Feb 12Earnings beat expectations, revenue disappointsRevenue missed analyst estimates by 2.9%. Earnings per share (EPS) exceeded analyst estimates by 2.9%. Over the next year, revenue is expected to shrink by 67% compared to a 819% growth forecast for the Biotechs industry in the US.
Is New 90 Day High Low • Feb 04New 90-day high: US$3.30The company is up 37% from its price of US$2.41 on 05 November 2020. The American market is up 16% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 24% over the same period.
分析記事 • Jan 14How Much Of Genocea Biosciences, Inc. (NASDAQ:GNCA) Do Institutions Own?Every investor in Genocea Biosciences, Inc. ( NASDAQ:GNCA ) should be aware of the most powerful shareholder groups...
Is New 90 Day High Low • Dec 24New 90-day high: US$2.67The company is up 26% from its price of US$2.12 on 24 September 2020. The American market is up 18% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 23% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.
Is New 90 Day High Low • Oct 31New 90-day low: US$2.08The company is down 27% from its price of US$2.85 on 31 July 2020. The American market is up 3.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 2.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is US$11.76 per share.
Analyst Estimate Surprise Post Earnings • Oct 31Third-quarter earnings released: Earnings beat expectationsEarnings per share (EPS) surpassed analyst estimates by 69% at -US$0.08. Revenue is expected to shrink by 76% over the next year, compared to a 293% growth forecast for the Biotechs industry in the US.
Major Estimate Revision • Oct 30Analysts increase EPS estimates to -US$1.07The 2020 consensus revenue estimate increased from US$922.4k to US$937.3k. Analysts raised their EPS forecasts from -US$1.21 to -US$1.07 in 2020. The Biotechs industry in the US is expected to see an average net income growth of 6.3% next year. The consensus price target of US$9.40 was unchanged from the last update. Share price is down by 8.6% to US$2.12 over the past week.
Major Estimate Revision • Sep 18Analysts update estimatesThe 2020 consensus revenue estimate increased from US$722.4k to US$922.4k. Earning per share (EPS) estimate remained mostly unchanged at -US$1.21. The Biotechs industry in the US is expected to see a 17% decline in net income next year. The consensus price target of US$9.40 was unchanged from the last update. Share price is up 17% to US$2.54 over the past week.